Recruiting

Genetic Testing

Sponsor:

Massachusetts General Hospital

Code:

NCT01719211

Conditions

Mitral Valve Prolapse

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The investigators have successfully identified two novel genetic loci for MVP on chromosomes 11 and 13 and are searching for altered genes in these regions. This requires recruiting large families who may have MVP linked to these or other chromosomes; and obtaining DNA samples from 1,000-1,500 individually affected patients to study the relation between DNA markers throughout the genome and MVP. It is our expectation that the results of this study will lead to the discovery of gene(s) responsible for MVP. This will lead to improved understanding of the disease and, in turn, improved ability to treat and prevent progression in genetically susceptible individuals.

Conditions

Mitral Valve Prolapse

Study ID

NCT01719211

Start date

Jan, 1999

Status verified date

Nov, 2023

Completion date

Dec, 2025

Anticipated

Primary completion date

Dec, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Mitral valve prolapse

Exclusion Criteria:

  • Other mitral valve diseases

Study Design

Enrollment

1500 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Discovery of the genetic basis of Mitral Valve Prolapse [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Locations

Mass General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

More Information

Sponsor

Massachusetts General Hospital

Last update posted

Nov 8, 2023

Last verified

Nov, 2023

Keywords

  • MVP, mitral valve

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2023-11-08.